{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:52:59Z","timestamp":1793404379562,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-025-01706-w","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T01:25:06Z","timestamp":1742001906000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Beyond expectations: investigating nilotinib\u2019s potential in attenuating neurodegeneration in Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"17","author":[{"given":"Darcy","family":"Tocci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiah","family":"Fogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanya","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Latimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Adlimoghaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa S.","family":"Robison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedict C.","family":"Albensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"key":"1706_CR1","doi-asserted-by":"publisher","first-page":"117996","DOI":"10.1016\/j.lfs.2020.117996","volume":"256","author":"A Abeysinghe","year":"2020","unstructured":"Abeysinghe A, Deshapriya R, Udawatte C. Alzheimer\u2019s disease; a review of the pathophysiological basis and therapeutic interventions. Life Sci Sep 1. 2020;256:117996. https:\/\/doi.org\/10.1016\/j.lfs.2020.117996.","journal-title":"Life Sci Sep 1"},{"key":"1706_CR2","doi-asserted-by":"publisher","unstructured":"2021 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. Mar 2021;17(3):327\u2013406. https:\/\/doi.org\/10.1002\/alz.12328","DOI":"10.1002\/alz.12328"},{"issue":"1\u20132","key":"1706_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000490414","volume":"51","author":"A Adlimoghaddam","year":"2018","unstructured":"Adlimoghaddam A, Roy B, Albensi BC. Future trends and the economic burden of dementia in Manitoba: comparison with the rest of Canada and the world. Neuroepidemiology. 2018;51(1\u20132):71\u201381. https:\/\/doi.org\/10.1159\/000490414.","journal-title":"Neuroepidemiology"},{"key":"1706_CR4","doi-asserted-by":"publisher","unstructured":"Cai W, Wu T, Chen N. The Amyloid-Beta clearance: from molecular targets to glial and neural cells. Biomolecules Feb. 2023;7(2). https:\/\/doi.org\/10.3390\/biom13020313.","DOI":"10.3390\/biom13020313"},{"issue":"4","key":"1706_CR5","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.psc.2022.07.003","volume":"45","author":"BC Yarns","year":"2022","unstructured":"Yarns BC, Holiday KA, Carlson DM, Cosgrove CK, Melrose RJ. Pathophysiology of Alzheimer\u2019s disease. Psychiatr Clin North Am Dec. 2022;45(4):663\u201376. https:\/\/doi.org\/10.1016\/j.psc.2022.07.003.","journal-title":"Psychiatr Clin North Am Dec"},{"issue":"3","key":"1706_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7861\/clinmedicine.16-3-247","volume":"16","author":"R Briggs","year":"2016","unstructured":"Briggs R, Kennelly SP, O\u2019Neill D. Drug treatments in Alzheimer\u2019s disease. Clin Med (Lond) Jun. 2016;16(3):247\u201353. https:\/\/doi.org\/10.7861\/clinmedicine.16-3-247.","journal-title":"Clin Med (Lond) Jun"},{"key":"1706_CR7","doi-asserted-by":"publisher","first-page":"117957352090739","DOI":"10.1177\/1179573520907397","volume":"12","author":"KG Yiannopoulou","year":"2020","unstructured":"Yiannopoulou KG, Papageorgiou SG. Current and future treatments in alzheimer disease: an update. J Cent Nerv Syst Dis. 2020;12:1179573520907397. https:\/\/doi.org\/10.1177\/1179573520907397.","journal-title":"J Cent Nerv Syst Dis"},{"key":"1706_CR8","unstructured":"Sebasti\u00e3o A. Alzheimer\u2019s Disease (AD) - Current Treatments. BioRender. p. Visualization of current drugs (Donepezil, Rivastigmine, Galantamine, Memantine) mechanism of action for Alzheimer\u2019s Disease (AD)."},{"key":"1706_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2147\/cia.s6666","volume":"4","author":"SJ Thomas","year":"2009","unstructured":"Thomas SJ, Grossberg GT. Memantine: a review of studies into its safety and efficacy in treating Alzheimer\u2019s disease and other dementias. Clin Interv Aging. 2009;4:367\u201377. https:\/\/doi.org\/10.2147\/cia.s6666.","journal-title":"Clin Interv Aging"},{"issue":"4","key":"1706_CR10","doi-asserted-by":"publisher","first-page":"e0123289","DOI":"10.1371\/journal.pone.0123289","volume":"10","author":"S Matsunaga","year":"2015","unstructured":"Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer\u2019s disease: a systematic review and meta-analysis. PLoS ONE. 2015;10(4):e0123289. https:\/\/doi.org\/10.1371\/journal.pone.0123289.","journal-title":"PLoS ONE"},{"key":"1706_CR11","doi-asserted-by":"publisher","unstructured":"Hoy SM, Lecanemab. First approval. Drugs Mar. 2023;83(4):359\u201365. https:\/\/doi.org\/10.1007\/s40265-023-01851-2.","DOI":"10.1007\/s40265-023-01851-2"},{"issue":"1","key":"1706_CR12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3233\/ADR-230025","volume":"7","author":"DA Loeffler","year":"2023","unstructured":"Loeffler DA. Antibody-Mediated clearance of brain Amyloid-beta: mechanisms of action, effects of natural and monoclonal Anti-Abeta antibodies, and downstream effects. J Alzheimers Dis Rep. 2023;7(1):873\u201399. https:\/\/doi.org\/10.3233\/ADR-230025.","journal-title":"J Alzheimers Dis Rep"},{"key":"1706_CR13","doi-asserted-by":"publisher","unstructured":"Low ZY, Farouk IA, Lal SK. Drug repositioning: new approaches and future prospects for Life-Debilitating diseases and the COVID-19 pandemic outbreak. Viruses Sep. 2020;22(9). https:\/\/doi.org\/10.3390\/v12091058.","DOI":"10.3390\/v12091058"},{"issue":"12","key":"1706_CR14","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41582-020-0397-4","volume":"16","author":"C Ballard","year":"2020","unstructured":"Ballard C, Aarsland D, Cummings J, et al. Drug repositioning and repurposing for alzheimer disease. Nat Rev Neurol Dec. 2020;16(12):661\u201373. https:\/\/doi.org\/10.1038\/s41582-020-0397-4.","journal-title":"Nat Rev Neurol Dec"},{"issue":"1","key":"1706_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s12539-021-00487-8","volume":"14","author":"F Yang","year":"2022","unstructured":"Yang F, Zhang Q, Ji X, et al. Machine learning applications in drug repurposing. Interdiscip Sci Mar. 2022;14(1):15\u201321. https:\/\/doi.org\/10.1007\/s12539-021-00487-8.","journal-title":"Interdiscip Sci Mar"},{"issue":"4","key":"1706_CR16","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.trci.2017.10.002","volume":"3","author":"A Judge","year":"2017","unstructured":"Judge A, Garriga C, Arden NK, et al. Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients. Alzheimers Dement (N Y) Nov. 2017;3(4):612\u201321. https:\/\/doi.org\/10.1016\/j.trci.2017.10.002.","journal-title":"Alzheimers Dement (N Y) Nov"},{"issue":"11","key":"1706_CR17","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nrd3869","volume":"11","author":"A Corbett","year":"2012","unstructured":"Corbett A, Pickett J, Burns A, et al. Drug repositioning for Alzheimer\u2019s disease. Nat Rev Drug Discov Nov. 2012;11(11):833\u201346. https:\/\/doi.org\/10.1038\/nrd3869.","journal-title":"Nat Rev Drug Discov Nov"},{"issue":"1","key":"1706_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41746-022-00617-6","volume":"14","author":"N Zong","year":"2022","unstructured":"Zong N, Wen A, Moon S, et al. Computational drug repurposing based on electronic health records: a scoping review. NPJ Digit Med Jun. 2022;14(1):77. https:\/\/doi.org\/10.1038\/s41746-022-00617-6.","journal-title":"NPJ Digit Med Jun"},{"issue":"1","key":"1706_CR19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nrg2707","volume":"11","author":"P Lahiry","year":"2010","unstructured":"Lahiry P, Torkamani A, Schork NJ, Hegele RA. Kinase mutations in human disease: interpreting genotype-phenotype relationships. Nat Rev Genet Jan. 2010;11(1):60\u201374. https:\/\/doi.org\/10.1038\/nrg2707.","journal-title":"Nat Rev Genet Jan"},{"issue":"1","key":"1706_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12943-018-0788-y","volume":"19","author":"KS Siveen","year":"2018","unstructured":"Siveen KS, Prabhu KS, Achkar IW, et al. Role of Non receptor tyrosine kinases in hematological malignances and its targeting by natural products. Mol Cancer Feb. 2018;19(1):31. https:\/\/doi.org\/10.1186\/s12943-018-0788-y.","journal-title":"Mol Cancer Feb"},{"key":"1706_CR21","doi-asserted-by":"publisher","unstructured":"Azad T, Rezaei R, Surendran A, et al. Hippo signaling pathway as a central mediator of receptors tyrosine kinases (RTKs) in tumorigenesis. Cancers (Basel) Jul. 2020;24(8). https:\/\/doi.org\/10.3390\/cancers12082042.","DOI":"10.3390\/cancers12082042"},{"issue":"1","key":"1706_CR22","doi-asserted-by":"publisher","first-page":"e12044","DOI":"10.1002\/trc2.12044","volume":"6","author":"F Fagiani","year":"2020","unstructured":"Fagiani F, Lanni C, Racchi M, Govoni S. Targeting dementias through cancer kinases Inhibition. Alzheimers Dement (N Y). 2020;6(1):e12044. https:\/\/doi.org\/10.1002\/trc2.12044.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"4","key":"1706_CR23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s12272-018-1094-3","volume":"42","author":"DH Jo","year":"2019","unstructured":"Jo DH, Kim JH, Kim JH. Targeting tyrosine kinases for treatment of ocular tumors. Arch Pharm Res Apr. 2019;42(4):305\u201318. https:\/\/doi.org\/10.1007\/s12272-018-1094-3.","journal-title":"Arch Pharm Res Apr"},{"issue":"2","key":"1706_CR24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.7150\/ijms.1.101","volume":"1","author":"MK Paul","year":"2004","unstructured":"Paul MK, Mukhopadhyay AK. Tyrosine kinase - Role and significance in Cancer. Int J Med Sci. 2004;1(2):101\u201315. https:\/\/doi.org\/10.7150\/ijms.1.101.","journal-title":"Int J Med Sci"},{"issue":"1","key":"1706_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0167-4889(98)00178-5","volume":"4","author":"PW Schenk","year":"1999","unstructured":"Schenk PW, Snaar-Jagalska BE. Signal perception and transduction: the role of protein kinases. Biochim Biophys Acta Feb. 1999;4(1):1\u201324. https:\/\/doi.org\/10.1016\/s0167-4889(98)00178-5.","journal-title":"Biochim Biophys Acta Feb"},{"issue":"Pt 1","key":"1706_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20030407","volume":"15","author":"PC Heinrich","year":"2003","unstructured":"Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of Interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J Aug. 2003;15(Pt 1):1\u201320. https:\/\/doi.org\/10.1042\/BJ20030407.","journal-title":"Biochem J Aug"},{"key":"1706_CR27","doi-asserted-by":"publisher","first-page":"108171","DOI":"10.1016\/j.pharmthera.2022.108171","volume":"237","author":"M Eshraghi","year":"2022","unstructured":"Eshraghi M, Ahmadi M, Afshar S, et al. Enhancing autophagy in Alzheimer\u2019s disease through drug repositioning. Pharmacol Ther Sep. 2022;237:108171. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108171.","journal-title":"Pharmacol Ther Sep"},{"issue":"10","key":"1706_CR28","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"15","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following Imatinib resistance and intolerance. Blood Nov. 2007;15(10):3540\u20136. https:\/\/doi.org\/10.1182\/blood-2007-03-080689.","journal-title":"Blood Nov"},{"issue":"11","key":"1706_CR29","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"13","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med Mar. 2003;13(11):994\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa022457.","journal-title":"N Engl J Med Mar"},{"issue":"12","key":"1706_CR30","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","volume":"19","author":"E Weisberg","year":"2006","unstructured":"Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer Jun. 2006;19(12):1765\u20139. https:\/\/doi.org\/10.1038\/sj.bjc.6603170.","journal-title":"Br J Cancer Jun"},{"issue":"2","key":"1706_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5306\/wjco.v12.i2.69","volume":"24","author":"MM Sampaio","year":"2021","unstructured":"Sampaio MM, Santos MLC, Marques HS, et al. Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review. World J Clin Oncol Feb. 2021;24(2):69\u201394. https:\/\/doi.org\/10.5306\/wjco.v12.i2.69.","journal-title":"World J Clin Oncol Feb"},{"issue":"4","key":"1706_CR32","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","volume":"15","author":"D Cilloni","year":"2012","unstructured":"Cilloni D, Saglio G. Molecular pathways: BCR-ABL. Clin Cancer Res Feb. 2012;15(4):930\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1613.","journal-title":"Clin Cancer Res Feb"},{"issue":"1","key":"1706_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/mds.28858","volume":"37","author":"MH Werner","year":"2022","unstructured":"Werner MH, Olanow CW. Parkinson\u2019s disease modification through Abl kinase Inhibition: an opportunity. Mov Disord Jan. 2022;37(1):6\u201315. https:\/\/doi.org\/10.1002\/mds.28858.","journal-title":"Mov Disord Jan"},{"issue":"1","key":"1706_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/path.2697","volume":"221","author":"D Glick","year":"2010","unstructured":"Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J Pathol May. 2010;221(1):3\u201312. https:\/\/doi.org\/10.1002\/path.2697.","journal-title":"J Pathol May"},{"key":"1706_CR35","doi-asserted-by":"publisher","unstructured":"Fellner L, Gabassi E, Haybaeck J, Edenhofer F. Autophagy in alpha-Synucleinopathies-An overstrained system. Cells Nov. 2021;12(11). https:\/\/doi.org\/10.3390\/cells10113143.","DOI":"10.3390\/cells10113143"},{"issue":"5","key":"1706_CR36","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1080\/15548627.2021.1909409","volume":"17","author":"A Nobili","year":"2021","unstructured":"Nobili A, La Barbera L, D\u2019Amelio M. Targeting autophagy as a therapeutic strategy to prevent dopamine neuron loss in early stages of alzheimer disease. Autophagy May. 2021;17(5):1278\u201380. https:\/\/doi.org\/10.1080\/15548627.2021.1909409.","journal-title":"Autophagy May"},{"key":"1706_CR37","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.1038\/srep04874","volume":"4","author":"SS Karuppagounder","year":"2014","unstructured":"Karuppagounder SS, Brahmachari S, Lee Y, Dawson VL, Dawson TM, Ko HS. The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson\u2019s disease. Sci Rep May 2. 2014;4:4874. https:\/\/doi.org\/10.1038\/srep04874.","journal-title":"Sci Rep May 2"},{"issue":"16","key":"1706_CR38","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1093\/hmg\/ddt192","volume":"15","author":"ML Hebron","year":"2013","unstructured":"Hebron ML, Lonskaya I, Moussa CE. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson\u2019s disease models. Hum Mol Genet Aug. 2013;15(16):3315\u201328. https:\/\/doi.org\/10.1093\/hmg\/ddt192.","journal-title":"Hum Mol Genet Aug"},{"key":"1706_CR39","doi-asserted-by":"publisher","first-page":"108025","DOI":"10.1016\/j.intimp.2021.108025","volume":"99","author":"J Wu","year":"2021","unstructured":"Wu J, Xu X, Zheng L, Mo J, Jin X, Bao Y. Nilotinib inhibits microglia-mediated neuroinflammation to protect against dopaminergic neuronal death in Parkinson\u2019s disease models. Int Immunopharmacol Oct. 2021;99:108025. https:\/\/doi.org\/10.1016\/j.intimp.2021.108025.","journal-title":"Int Immunopharmacol Oct"},{"key":"1706_CR40","doi-asserted-by":"publisher","first-page":"835563","DOI":"10.3389\/fonc.2022.835563","volume":"12","author":"A Sicuranza","year":"2022","unstructured":"Sicuranza A, Ferrigno I, Abruzzese E, et al. Pro-Inflammatory and Pro-Oxidative changes during nilotinib treatment in CML patients: results of a prospective multicenter Front-Line TKIs study (KIARO study). Front Oncol. 2022;12:835563. https:\/\/doi.org\/10.3389\/fonc.2022.835563.","journal-title":"Front Oncol"},{"issue":"8","key":"1706_CR41","doi-asserted-by":"publisher","first-page":"102238","DOI":"10.1016\/j.jbc.2022.102238","volume":"298","author":"B Oruganti","year":"2022","unstructured":"Oruganti B, Lindahl E, Yang J, Amiri W, Rahimullah R, Friedman R. Allosteric enhancement of the BCR-Abl1 kinase Inhibition activity of nilotinib by cobinding of asciminib. J Biol Chem Aug. 2022;298(8):102238. https:\/\/doi.org\/10.1016\/j.jbc.2022.102238.","journal-title":"J Biol Chem Aug"},{"issue":"7","key":"1706_CR42","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.clinthera.2021.05.009","volume":"43","author":"X Gong","year":"2021","unstructured":"Gong X, Li L, Wei H, et al. A higher dose of dasatinib May increase the possibility of crossing the Blood-brain barrier in the treatment of patients with Philadelphia Chromosome-positive acute lymphoblastic leukemia. Clin Ther Jul. 2021;43(7):1265\u2013e12711. https:\/\/doi.org\/10.1016\/j.clinthera.2021.05.009.","journal-title":"Clin Ther Jul"},{"issue":"4","key":"1706_CR43","doi-asserted-by":"publisher","first-page":"803","DOI":"10.4103\/1673-5374.350700","volume":"18","author":"A Nobili","year":"2023","unstructured":"Nobili A, D\u2019Amelio M, Viscomi MT. Nilotinib: from animal-based studies to clinical investigation in Alzheimer\u2019s disease patients. Neural Regen Res Apr. 2023;18(4):803\u20134. https:\/\/doi.org\/10.4103\/1673-5374.350700.","journal-title":"Neural Regen Res Apr"},{"key":"1706_CR44","unstructured":"Teber K. Nilotinib appears safe and affects biomarkers in Alzheimer\u2019s disease clinical trial. Georget Univ. 2024. https:\/\/gumc.georgetown.edu\/news-release\/nilotinib-appears-safe-and-affects-biomarkers-in-alzheimers-disease-clinical-trial\/#"},{"issue":"1","key":"1706_CR45","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ana.25775","volume":"88","author":"RS Turner","year":"2020","unstructured":"Turner RS, Hebron ML, Lawler A, et al. Nilotinib effects on safety, tolerability, and biomarkers in Alzheimer\u2019s disease. Ann Neurol Jul. 2020;88(1):183\u201394. https:\/\/doi.org\/10.1002\/ana.25775.","journal-title":"Ann Neurol Jul"},{"key":"1706_CR46","unstructured":"Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer\u2019s Disease (NILEAD). National library of medicine. Updated 12\/03\/2021. Accessed 05\/06, 2024. https:\/\/clinicaltrials.gov\/study\/NCT05143528?tab=table"},{"issue":"2","key":"1706_CR47","doi-asserted-by":"publisher","first-page":"441","DOI":"10.14336\/AD.2020.0910","volume":"12","author":"A Adlimoghaddam","year":"2021","unstructured":"Adlimoghaddam A, Odero GG, Glazner G, Turner RS, Albensi BC. Nilotinib improves bioenergetic profiling in brain astroglia in the 3xTg mouse model of Alzheimer\u2019s disease. Aging Dis Apr. 2021;12(2):441\u201365. https:\/\/doi.org\/10.14336\/AD.2020.0910.","journal-title":"Aging Dis Apr"},{"issue":"25","key":"1706_CR48","doi-asserted-by":"publisher","first-page":"18249","DOI":"10.1074\/jbc.M112.446385","volume":"21","author":"HC Yu","year":"2013","unstructured":"Yu HC, Lin CS, Tai WT, Liu CY, Shiau CW, Chen KF. Nilotinib induces autophagy in hepatocellular carcinoma through AMPK activation. J Biol Chem Jun. 2013;21(25):18249\u201359. https:\/\/doi.org\/10.1074\/jbc.M112.446385.","journal-title":"J Biol Chem Jun"},{"issue":"1","key":"1706_CR49","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","volume":"7","author":"S Shyam Sunder","year":"2023","unstructured":"Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther Jul. 2023;7(1):262. https:\/\/doi.org\/10.1038\/s41392-023-01469-6.","journal-title":"Signal Transduct Target Ther Jul"},{"issue":"7","key":"1706_CR50","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/leu.2017.63","volume":"31","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the enestfreedom study. Leuk Jul. 2017;31(7):1525\u201331. https:\/\/doi.org\/10.1038\/leu.2017.63.","journal-title":"Leuk Jul"},{"issue":"5","key":"1706_CR51","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41375-021-01205-5","volume":"35","author":"JP Radich","year":"2021","unstructured":"Radich JP, Hochhaus A, Masszi T, et al. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the enestfreedom trial. Leuk May. 2021;35(5):1344\u201355. https:\/\/doi.org\/10.1038\/s41375-021-01205-5.","journal-title":"Leuk May"},{"key":"1706_CR52","doi-asserted-by":"publisher","unstructured":"Kim JS, Han JM, Cho YS, Choi KH, Gwak HS. Machine learning approaches to predict hepatotoxicity risk in patients receiving nilotinib. Molecules May. 2021;31(11). https:\/\/doi.org\/10.3390\/molecules26113300.","DOI":"10.3390\/molecules26113300"},{"issue":"3","key":"1706_CR53","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s11136-021-02952-9","volume":"31","author":"CTT Nguyen","year":"2022","unstructured":"Nguyen CTT, Nguyen BT, Nguyen TTT, Petrelli F, Scuri S, Grappasonni I. Quality of life among chronic myeloid leukemia patients in the second-line treatment with nilotinib and influential factors. Qual Life Res Mar. 2022;31(3):733\u201343. https:\/\/doi.org\/10.1007\/s11136-021-02952-9.","journal-title":"Qual Life Res Mar"},{"issue":"2","key":"1706_CR54","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4274\/tjh.2016.0092","volume":"5","author":"G Cengiz Seval","year":"2017","unstructured":"Cengiz Seval G, Ozkavukcu S, Seval M, Ayli M. Gonadotoxic effects of nilotinib in chronic myeloid leukemia treatment dose in a mouse model. Turk J Haematol Jun. 2017;5(2):137\u201342. https:\/\/doi.org\/10.4274\/tjh.2016.0092. Kronik Miyeloid Losemi Tedavi Dozunda Nilotinib\u2019in Gonadotoksik Etkilerinin Fare Modelinde Gosterilmesi.","journal-title":"Turk J Haematol Jun"},{"issue":"12","key":"1706_CR55","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.clml.2020.08.009","volume":"20","author":"H Bostan","year":"2020","unstructured":"Bostan H, Toptas T, Tanrikulu FP, et al. Quality of life and symptom burden with First- and Second-generation tyrosine kinase inhibitors in patients with chronic-phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk Dec. 2020;20(12):836\u201342. https:\/\/doi.org\/10.1016\/j.clml.2020.08.009.","journal-title":"Clin Lymphoma Myeloma Leuk Dec"},{"issue":"3","key":"1706_CR56","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1530\/REP-20-0548","volume":"161","author":"S Ozkavukcu","year":"2021","unstructured":"Ozkavukcu S, Kuscu N, Adiguzel D, Cengiz-Seval G, Celik-Ozenci C. Deleterious reproductive effects of nilotinib in mouse model. Reprod Mar. 2021;161(3):295\u2013306. https:\/\/doi.org\/10.1530\/REP-20-0548.","journal-title":"Reprod Mar"},{"issue":"2","key":"1706_CR57","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00737-002-0144-4","volume":"5","author":"M Bonsignore","year":"2002","unstructured":"Bonsignore M, Barkow K, Heun R. Possible influence of selection bias on gender differences in the risk of Alzheimer\u2019s disease. Arch Womens Ment Health Oct. 2002;5(2):73\u20137. https:\/\/doi.org\/10.1007\/s00737-002-0144-4.","journal-title":"Arch Womens Ment Health Oct"},{"issue":"4","key":"1706_CR58","doi-asserted-by":"publisher","first-page":"437","DOI":"10.31887\/DCNS.2016.18.4\/cepperson","volume":"18","author":"JL Podcasy","year":"2016","unstructured":"Podcasy JL, Epperson CN. Considering sex and gender in alzheimer disease and other dementias. Dialogues Clin Neurosci Dec. 2016;18(4):437\u201346. https:\/\/doi.org\/10.31887\/DCNS.2016.18.4\/cepperson.","journal-title":"Dialogues Clin Neurosci Dec"},{"issue":"12","key":"1706_CR59","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1002\/alz.12662","volume":"18","author":"MM Mielke","year":"2022","unstructured":"Mielke MM, Aggarwal NT, Vila-Castelar C, et al. Consideration of sex and gender in Alzheimer\u2019s disease and related disorders from a global perspective. Alzheimers Dement Dec. 2022;18(12):2707\u201324. https:\/\/doi.org\/10.1002\/alz.12662.","journal-title":"Alzheimers Dement Dec"},{"issue":"1","key":"1706_CR60","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1186\/s12885-019-6039-9","volume":"28","author":"L Tang","year":"2019","unstructured":"Tang L, Zhang H, Peng YZ, et al. Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis. BMC Cancer Aug. 2019;28(1):849. https:\/\/doi.org\/10.1186\/s12885-019-6039-9.","journal-title":"BMC Cancer Aug"},{"issue":"12","key":"1706_CR61","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1182\/bloodadvances.2019001329","volume":"23","author":"C Vener","year":"2020","unstructured":"Vener C, Banzi R, Ambrogi F, et al. First-line Imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis. Blood Adv Jun. 2020;23(12):2723\u201335. https:\/\/doi.org\/10.1182\/bloodadvances.2019001329.","journal-title":"Blood Adv Jun"},{"key":"1706_CR62","doi-asserted-by":"publisher","first-page":"996217","DOI":"10.3389\/fnagi.2022.996217","volume":"14","author":"X Xie","year":"2022","unstructured":"Xie X, Yuan P, Kou L, Chen X, Li J, Li Y. Nilotinib in Parkinson\u2019s disease: A systematic review and meta-analysis. Front Aging Neurosci. 2022;14:996217. https:\/\/doi.org\/10.3389\/fnagi.2022.996217.","journal-title":"Front Aging Neurosci"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01706-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01706-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01706-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T08:21:29Z","timestamp":1745223689000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01706-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1706"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01706-w","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]},"assertion":[{"value":"6 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}